340B Contract Pharmacy Arrangements: What Does the Future Hold?
|
|
- Archibald Daniel
- 6 years ago
- Views:
Transcription
1 Presenting a live 90-minute webinar with interactive Q&A 340B Contract Pharmacy Arrangements: What Does the Future Hold? Structuring Arrangements, Meeting Legal and Regulatory Requirements THURSDAY, DECEMBER 21, pm Eastern 12pm Central 11am Mountain 10am Pacific Today s faculty features: Travis F. Jackson, Partner, King & Spalding, Los Angeles Claire F. Miley, Member, Bass Berry & Sims, Nashville, Tenn. The audio portion of the conference may be accessed via the telephone or by using your computer's speakers. Please refer to the instructions ed to registrants for additional information. If you have any questions, please contact Customer Service at ext. 10.
2 Tips for Optimal Quality FOR LIVE EVENT ONLY Sound Quality If you are listening via your computer speakers, please note that the quality of your sound will vary depending on the speed and quality of your internet connection. If the sound quality is not satisfactory, you may listen via the phone: dial and enter your PIN when prompted. Otherwise, please send us a chat or sound@straffordpub.com immediately so we can address the problem. If you dialed in and have any difficulties during the call, press *0 for assistance. Viewing Quality To maximize your screen, press the F11 key on your keyboard. To exit full screen, press the F11 key again.
3 Continuing Education Credits FOR LIVE EVENT ONLY In order for us to process your continuing education credit, you must confirm your participation in this webinar by completing and submitting the Attendance Affirmation/Evaluation after the webinar. A link to the Attendance Affirmation/Evaluation will be in the thank you that you will receive immediately following the program. For additional information about continuing education, call us at ext. 35.
4 Program Materials FOR LIVE EVENT ONLY If you have not printed the conference materials for this program, please complete the following steps: Click on the ^ symbol next to Conference Materials in the middle of the lefthand column on your screen. Click on the tab labeled Handouts that appears, and there you will see a PDF of the slides for today's program. Double click on the PDF and a separate page will open. Print the slides by clicking on the printer icon.
5 340B Contract Pharmacy Arrangements: What Does the Future Hold? December 21,
6 Outline I. Structuring and implementing contract pharmacy arrangements A. Overview and need for services B. Due diligence C. Fee structures D. What operational and contractual considerations should counsel keep in mind when structuring and implementing these arrangements? E. What compliance challenges must be overcome when structuring a contract pharmacy arrangement? II. 340B entity compliance issues A. Certifications B. Contractor-associated liability C. Covered entity requirements III. A look ahead A. Enforcement and sanctions B. Future of 340B Guidance 6
7 Overview and Need For Services 7
8 340B Program Overview The 340B Drug Pricing Program requires drug manufacturers who participate in Medicaid to provide outpatient drugs to eligible healthcare organizations ( Covered Entities, or CEs ) at significantly reduced prices. 8
9 340B Program Overview CEs receive significant discounts on covered outpatient drugs Estimated average savings of 20-50% Estimated $16 billion in 340B drug purchases in 2016 (5% of U.S. Drug Market), per Drug Channels CEs are defined in statute and include HRSA-supported health centers, Ryan White clinics and State AIDS Drug Assistance programs, Medicare/Medicaid Disproportionate Share Hospitals, children s hospitals, and other safety net providers. 9
10 340B Program Overview: Contract Pharmacies HRSA permits CEs to contract with pharmacies to provide pharmacy services on the CE s behalf to CE patients. Initially, CEs were limited to one contract pharmacy relationship In 2010, HRSA allowed CEs to enter into multiple contract pharmacy relationships Contract pharmacies ( CPs ) are a growth area, but also one under OIG, GAO, and manufacturer scrutiny 10
11 Contract Pharmacy Arrangement: Example Process Flow Wholesaler Drugs shipped to CP CE purchases 340B Drugs Payer CP adjudicates script Payer reimburses CP CP dispenses; collects Patient cost-share Contract Pharmacy Patient CP remits reimbursement less fee Covered Entity 340B eligible patient relationship 11
12 Need For Contract Pharmacy Services HRSA: [T]he delivery of pharmacy services is central to the mission of covered entities, which rely on outside pharmacies to fill the need. It would defeat the purpose of the 340B program if these covered entities could not use their affiliated pharmacies in order to participate in the 340B program [emphasis supplied]. 61 Fed. Reg , (Aug. 23, 1996). BUT, there is growing backlash among some 340B stakeholders to CP arrangements There is also growing government scrutiny of the 340B program in general 12
13 Congressional Scrutiny Extensive number of Congressional hearings Potential draft legislation discussed in May 2017: At a trade association event, Rep. Collins (R-NY) promised to introduce 340B reform legislation Reports indicate that the proposed bill would narrow the eligible patient definition, limit new CE enrollment, limit CPs, and expand HRSA oversight of the program Has not been introduced in Congress Even if the Rep. Collins legislation does not materialize, we do expect some legislative package, which may contain one or more of the following: Definition of patient Limits on contract pharmacies (e.g., by number and/or location) Limits on charges for 340B drugs Required reporting of amount and use of 340B savings 13
14 Congressional Scrutiny July 2017 Testimony of GAO Before Congress Update on Agency Efforts to Improve 340B Program Oversight Highlights of Testimony: HRSA Audits Clarifying Program Guidance on - Definition of Patient - Eligibility Criteria for non-publicly owned hospitals Due in Oversight of 340B Contract Pharmacies 14
15 Reimbursement 340B Trend to Watch Government Program Capture of 340B Savings 2018: Final Medicare OPPS Rule Cuts the applicable payment rate for separately payable drugs and biologicals (other than drugs on pass-through payment status and vaccines) acquired under the 340B program from average sales price (ASP) plus 6 percent to ASP minus 22.5 percent. Exemptions for certain rural sole community hospitals, CAHs, PPS-exempt cancer hospitals, and HOPDs subject to site neutrality rules 15
16 Reimbursement 340B Trend to Watch Government Program Capture of 340B Savings 2018: Final Medicare OPPS Rule The AHA and other advocacy groups filed suit against HHS on11/13/17. The complaint alleges that HHS s rulemaking was: - arbitrary and capricious; and/or - contrary to law; and - is in excess of the agency s statutory authority. 16
17 Reimbursement 340B Trend to Watch Government Program Capture of 340B Savings 2018: Final Medicare OPPS Rule Rep. David McKinley (R-WV) introduced H.R to block the 340B OPPS cuts on 11/14/17 Bill has been referred to the House Committee on Energy and Commerce and the House Ways and Means Committee 17
18 Reimbursement 340B Trend to Watch Government Program Capture of 340B Savings 2016: Medicaid Covered Outpatient Drug Rule [T]his final rule is designed to ensure that pharmacy reimbursement is aligned with the acquisition cost of drugs and that the states pay an appropriate professional dispensing fee. Requires States to transition to AAC-based methodology for pharmacy reimbursement 18
19 Reimbursement What Effect on Contract Pharmacies? OPPS cut due to take effect January 1, 2018 If cuts survive, the 340B program will likely become less attractive to covered entity hospitals Therefore, despite the recent boom in contract pharmacies, will they dry up in the future? 19
20 340B Program Overview: Contract Pharmacies Contract pharmacy growth has perhaps leveled off: Per Apexus: Date # of Unique 340B CPs % Growth 1/1/12 4,238 1/1/13 9, % 1/1/14 13,707 39% 1/1/15 16,269 19% 1/1/16 17,463 7% 20 1/1/17 18,705 7%
21 21 Due Diligence
22 Contract Pharmacy Due Diligence Three Areas of Inquiry 1. The Pharmacy 2. The Vendor 3. The Covered Entity 22
23 The Pharmacy What is the business justification for the contract pharmacy relationship? What is the pharmacy s compliance record? Is the pharmacy a good fit for the covered entity s culture? What processes does the pharmacy have in place to ensure 340B outpatient drugs are dispensed only to qualifying patients? How does the pharmacy store prescription records? Is the pharmacy equipped to connect to the covered entity through its EHR? What restrictions might exist on the pharmacy through managed care or vendor agreements? 23
24 The Vendor What is the vendor s experience and reputation? Is the vendor a good cultural fit for the covered entity? Does the vendor offer a system that supports compliance? Identifying eligible patients Preventing duplicate discounts How does the vendor support inventory management? What are the vendor s reporting capabilities? How is the fee structured? Does the covered entity control the revenue? 24
25 The Covered Entity Is the contract pharmacy network exclusive? What is the pharmacy s role and responsibilities in audits? Will the engagement affect any wholesaler arrangements? Will the engagement impact any rebates? What miscellaneous costs might exist, e.g. EHR and additional oversight? What is the covered entity s compliance record? Is the covered entity a good cultural fit? 25
26 26 Fee Structures
27 Fee structures HRSA permits CEs and CPs wide flexibility to develop mutually acceptable fee structures Compensation must comply with state and federal fraud and abuse requirements 27
28 Fee structures In a typical contract pharmacy arrangement, the contract pharmacy receives a fixed dispensing fee for each 340B prescription dispensed. Many contract pharmacy arrangements also use what is known as a replenishment model CP uses its own inventory initially Accumulator software is used after the fact to tally the eligible 340B patients from records of prior prescriptions CE then replenishes the inventory, in an amount equaling the actual prior usage by such eligible patients, with covered drugs purchased at the discounted 340B price from manufacturers. 28
29 Typical Financial Arrangement Pass-Through Model Transaction Payments CP buys initial inventory $100 CP bills payer $120 CP collects co-pay $20 CP collects reimbursement $100 CP transfers total reimbursement to CE $120 CE pays CP fixed dispensing fee for the 340B prescription (if not already netted out of reimbursement transferred to CE) $20 CE pays for replenishment inventory $60 29 Gross Margin to CP (dispensing fee) $20 Gross Margin to CE (reimbursement COGs dispensing fee) $40
30 Other Fee structures Tiered Dispensing Fees What drives the tier? Payer Reimbursement Amount Cost of Drug Variations of Per Rx Dispense Fees Per Processed Claim Per Eligible Claim 30
31 Other Fee structures Flat Monthly Fees Percentage of Collections Fees Reference Pricing Model Combinations and Add-On Fees 31
32 Operational and Contractual Considerations 32
33 Operational Considerations The Compliance Challenge Applying the covered entity s policies and procedures to the contract pharmacy Patient definition GPO prohibition Ensuring adequate oversight of the day-to-day contract pharmacy operations Contract pharmacy registration Conducting internal and external audits Understanding financial expectations Third party payors Financial assistance Dispensing fees 33
34 Operational Considerations The IT Challenge Incorporating all necessary data components to identify eligible patients Minimizing/eliminating manual processes Understanding inventory management protocols Replenishment True Ups Formulary Making appropriate payments 34
35 Operational Considerations The People Challenge Developing policies and procedures that allow covered entity and pharmacy employees to work as a team Identifying key contacts Understanding when and how audits will be conducted Discussing implementation or operational issues Developing a mechanism to resolve disputes 35
36 Contractual Considerations Vendor Agreement Fee Structure Application of other federal and state laws Non-Exclusivity Replenishment Reports 36
37 Contractual Considerations Contract Pharmacy Agreement HRSA Essential Covered Entity Compliance Elements Operational Needs The Compliance Challenge The IT Challenge The People Challenge Term and Termination Compliance with Laws Exclusivity v. Non-Exclusive 37
38 Contracting Compliance Challenges 38
39 Contracting Compliance Challenges: HRSA s 12 Essential Compliance Elements Ship to, Bill to Comprehensive Pharmacy Services Patient Choice 340B Pricing Restriction Compliance with law Contract Pharmacy Reporting Tracking System Patient Eligibility Verification Duplicate Discounts Prohibited Subject to Audits Maintain Auditable Records Provision of Agreement to OPA 39
40 Typical Roles Allocation of Functions Among Different Parties Underscores Need for Compliance Coordination Role Covered Entity Contract Pharmacy Admin Determine Patient Eligibility Dispense Drug and Provide Patient Care Track Replenishment and Prepare Order for Drug Order Replenishment Drug from Wholesaler Bill Payer Receive Reimbursement and Collect Copay Written Materials such as Policies and Procedures??? CE Training/Internal Audits??? Coordination with Account Managers, Operations, and IT for Items on COPs??? 40
41 Contracting Compliance Challenges Focus Areas Implementation of 2018 OPPS changes Modifier JG Includes PVP/Apexus drugs acquired at subceiling prices Modifier TB rural sole community hospitals, children s hospitals, and PPS-exempt cancer hospitals Required reporting of amount and use of savings Expected part of any legislative package 41
42 Contracting Compliance Challenges Focus Areas Prevention of Diversion and Potential Legislative Narrowing of Definition of Patient Duplicate Discounts, including Managed Medicaid No formal guidance from HRSA 2016 Medicaid managed care rule obligates plans to exclude 340B drugs from rebate claims BUT, still no standard reporting practices 42
43 Contracting Compliance Challenges Focus Areas Standard advice regarding carve out of Medicaid Claims at Contract Pharmacies vs. State Legislative Initiatives Overpayments from Payers 43
44 Contractor Liability? Compliance with 340B program rules is the sole responsibility of the CE A CP generally does not have direct exposure for program violations Therefore, CEs seek recourse against CPs and TPAs via contract provisions: Indemnification/consequential damages Insurance? 44
45 45 Certifications
46 Certifications 46
47 Certifications All information listed on the 340B Program database for the covered entity is complete, accurate and correct. The covered entity meets 340B Program eligibility requirements. The covered entity will comply with all requirements of the 340B Program, e.g.: Diversion Duplicate discounts GPO prohibition, if applicable The covered entity maintains auditable records pertaining to compliance with 340B Program requirements. Contract pharmacy arrangements will be performed in accordance with OPA requirements and guidelines. 47
48 Certifications Covered entity will contact OPA as soon as possible if a breach occurs or change in 340B Program eligibility. Covered entity may be liable to manufacturers for repayment and could be terminated from participating in the 340B Program. 48
49 Contract Pharmacy Registration Enrolling in the 340B Program is a multi-step process that varies based on entity type Must meet all eligibility criteria prior to registering with OPA Must register the calendar quarter prior to participating in the 340B Program Poor planning regarding eligibility and prospective registration requirements often result in improper or denied applications and the loss of significant savings / revenue 49
50 Contract Pharmacy Registration Covered entities must register contract pharmacies prior to use. A new contract pharmacy can only be registered during quarterly periods: Registration Periods Start Date January 1 15 April 1 April 1 15 July 1 July 1 15 October 1 October 1 15 January 1 50
51 Covered Entity Requirements 51
52 Covered Entity Requirements Eligibility Diversion GPO Prohibition* Duplicate Discount Prohibition Orphan Drug Exclusion** Contract Pharmacy Arrangements OPA Database Registration *DSHs, children s and cancer hospital only **SCHs, RRCs, CAHs and cancer hospitals only 52
53 Eligibility Hospitals Certain Disproportionate Share Hospitals Critical Access Hospitals Rural Referral Centers Sole Community Hospitals Children s Hospitals Free Standing Cancer Hospitals Federal Grantees 53 Comprehensive Hemophilia Treatment Centers Federally Qualified Health Centers Urban/638 Health Center Ryan White Programs Sexually Transmitted Disease/Tuberculosis Title X Family Planning
54 Hospital Eligibility Covered Entity Non- profit / govt contract DSH% GPO Exclusion Orphan Drug Exclusion Critical Access Hospital Yes No No Yes Rural Referral Center Yes > 8% No Yes Sole Community Hospital Free-Standing Cancer Hospitals Children s Hospitals Yes > 8% No Yes Yes >11.75% Yes Yes Yes >11.75% Yes No DSH Hospital Yes >11.75% Yes No 54
55 Diversion Diversion is strictly prohibited! 340B drugs can only be provided to eligible outpatients Cannot re-sell, give, or otherwise transfer 340B drugs to any other entity or individual Cannot loan or borrow 340B drugs to/from another entity Must maintain an audit trail for every dispensation 55
56 GPO Prohibition DSHs, children s hospitals and freestanding cancer hospitals may not obtain covered outpatient drugs through a group purchasing organization or other group purchasing arrangement February 7, 2013 HRSA Policy Release Sanctions for violating GPO prohibition can include, but are not limited to the following: Removal from the program Corrective action plans Repayments to wholesalers/manufacturers Examples of when the GPO prohibition applies: 340B outpatients Drugs that are not available at 340B pricing (must notify OPA) Carved-out Medicaid patients 56
57 GPO Prohibition GPOs come in many shapes and sizes GPO accounts may include: Traditional GPO accounts (Cardinal, McKesson, AmerisourceBergen, etc.) Generic source accounts Other collectively negotiated drug purchasing accounts (e.g. multi-covered entity health system) 57
58 Duplicate Discounts Manufacturers only required to provide 340B discount OR Medicaid (MCD) Drug Rebate Program rebate, not both Statute places onus on covered entity and state to ensure no duplicate discounts are obtained Must properly register with OPA/MCD Exclusion File Carve-in = 340B drugs to MCD patients; state will not seek rebates; on exclusion file Carve-out = non-340b drugs to MCD patients; state should seek rebates; not on exclusion file Contract pharmacies must carve-out unless a limited exception is met 58
59 Orphan Drug Exclusion An orphan drug is a drug designated by the FDA to treat a specific rare disease or condition Orphan drugs cannot be purchased at 340B rates if the covered entity is a rural referral center, sole community hospital, critical access hospital or freestanding cancer hospital. Manufacturers are not required to provide these covered entities orphan drugs under the 340B Program. A manufacturer may, at its sole discretion, offer discounts on orphan drugs to these hospitals 59
60 Contract Pharmacy Arrangements Examples of published OPA findings include: Covered entity was using a pharmacy with which it had a written contract in place, but the pharmacy was not listed on the 340B database Covered entity registered contract pharmacies on the 340B database without having written contracts in place Patients were ineligible for 340B 60
61 61 Enforcement and Sanctions
62 Enforcement and Sanctions - HRSA CEs are subject to audit by HRSA for compliance with 340B Program requirements, including CP requirements. HRSA regularly sanctions CEs for failing to comply with CP registration and oversight requirements. Sanctions include: manufacturer repayment; CE or CP termination from the 340B program; corrective action plan 62
63 HRSA Audit Expectations Annual Re-certifications Self-Disclosures/Material Breach Internal Investigations HRSA/OPA/Bizzell Audits 63
64 Enforcement and Sanctions - Manufacturers CEs are also subject to audit by manufacturers for violation of diversion or duplicate discount prohibitions. At least 45 days prior to conducting an audit, manufacturers must submit audit work plans to HRSA for review. Manufacturer audits must be performed by an independent auditor at the manufacturer s expense. CEs must respond to audit findings within 30 days. Unlike HRSA audits, results of manufacturer audits are not publically available. 64
65 Enforcement and Sanctions - Manufacturers Manufacturer Audit Guidelines: Number of Audits may only conduct audits when reasonable cause to believe a CE has violated 340B program requirements Scope of Audits audit work plan must be approved by HRSA. Limited to the manufacturer's drugs (not CE s entire 340B operations) Duration of Audits audit duration of no more than 1 year; performed with the minimum time and intrusion necessary 65
66 Enforcement and Sanctions - Manufacturers Post-Audit Procedures Manufacturer submits copy of final audit to CE, and CE has 30 days to respond with a corrective action proposal or grounds for disagreement. Manufacturer submits copies of final audit report & CE response to HRSA Potential sanctions (HRSA determines penalty): manufacturer repayment; termination of participation in 340B Program; corrective action plan 66
67 Enforcement and Sanctions HRSA has published the results of 103 audits of CEs for FY Of these, HRSA identified non-compliance with 340B Program requirements in about 45% of audits. 67
68 Examples of HRSA Sanctions Baptist Health Medical Center Arkadelphia (FY 2017) Audit Findings: - Diversion; 340B drugs dispensed at contract pharmacy for prescriptions written at ineligible sites Sanction Imposed: - Corrective Action Plan - Manufacturer Repayments 68
69 Examples of HRSA Sanctions Escambia Community Clinics, Inc. (FY 2017) Audit Findings: - Incorrect 340B database record; Registered contract pharmacies without written contracts in place. - Duplicate Discounts Sanction Imposed: - Termination of 2 CPs from 340B Program - Manufacturer Repayment - Corrective Action Plan 69
70 Examples of HRSA Sanctions San Joaquin Community Hospital (FY 2017) Audit Findings: - Entity s written contract pharmacy agreement listed information inconsistent with the 340B database record. - Diversion; 340B drugs were not properly accumulated. Sanction Imposed: - Manufacturer Repayments - Corrective Action Plan 70
71 Examples of HRSA Sanctions Southwest Memorial Hospital (FY 2017) Audit Findings: - Entity did not provide contract pharmacy oversight. - Diversion; 340B drugs dispensed at entity and at contract pharmacies for prescriptions written at ineligible sites. Sanction Imposed: - Termination of CPs from 340B Program - Manufacturer Repayments - Corrective Action Plan 71
72 72 Future of 340B Guidance
73 Where do we go from here? June 2017: Media reports cite a leaked draft executive order targeting the 340B Program. Resources provided by the 340B Program directed so they primarily benefit lower income or otherwise vulnerable Rescind or revise regulations or guidance that allow 340B Program benefits to accrue to entities or populations other than the safety net healthcare providers that the program was intended to strengthen 73
74 Where do we go from here? October 2017 Reportedly leaked policy document from the administration prescribes serious 340B reform. November 2017: 74 Joseph Grogan, associate director of health programs for the Office of Management and Budget, criticized the 340B program. President Trump nominates Alex Azar to be the next Secretary of the U.S. Department of Health & Human Services.
75 Questions? Contact Information: Travis F. Jackson, Claire F. Miley, 75
Structuring 340B Contract Pharmacy Arrangements: Meeting Legal and Regulatory Requirements
Presenting a live 90-minute webinar with interactive Q&A Structuring 340B Contract Pharmacy Arrangements: Meeting Legal and Regulatory Requirements WEDNESDAY, MARCH 19, 2014 1pm Eastern 12pm Central 11am
More informationCOMPLIANCE IN THE 340B DRUG PRICING PROGRAM
COMPLIANCE IN THE 340B DRUG PRICING PROGRAM Jason Atlas RPh MBA Manager, Education and Compliance Support Apexus Education and Compliance Support Team Apexus Education and Compliance Support Team 1 Objectives
More information340B: WHAT ATTORNEYS NEED TO KNOW TODAY, TOMORROW AND IN THE FUTURE. March 3, 2016 ABA Emerging Issues in Healthcare Conference San Diego, CA
340B: WHAT ATTORNEYS NEED TO KNOW TODAY, TOMORROW AND IN THE FUTURE March 3, 2016 ABA Emerging Issues in Healthcare Conference San Diego, CA 2 Presentation Outline What you need to know Today 340B Program
More informationMATERIAL COVERED TODAY
MATERIAL COVERED TODAY This presentation has been designed to discuss compliance needs, proposed changes and best practices for covered entities in the 340B Drug Pricing Program This presentation should
More informationThis training will begin at 12:00pm ET. WebEx Technical Support: Or us at
This training will begin at 12:00pm ET WebEx Technical Support: 1-866-229-3239 Or e-mail us at nationalhivcenter@fenwayhealth.org Works with HIV/AIDS service organizations and community-based organizations
More informationUniversal Health Services v. Escobar: Avoiding Implied Certification Liability Under FCA
Presenting a live 30-minute webinar with interactive Q&A Universal Health Services v. Escobar: Avoiding Implied Certification Liability Under FCA MONDAY, JULY 25, 2016 1pm Eastern 12pm Central 11am Mountain
More informationTHE 340B DRUG DISCOUNT PROGRAM AND INTERPLAY WITH MEDICARE AND MEDICAID REIMBURSEMENT PRINCIPLES. Barbara Straub Williams.
THE 340B DRUG DISCOUNT PROGRAM AND INTERPLAY WITH MEDICARE AND MEDICAID REIMBURSEMENT PRINCIPLES I. History and Purpose of 340B Program Barbara Straub Williams March 2015 Section 340B of the Public Health
More informationWebinar Schedule. I. A Guide to the 340B Omnibus Guidance 340B Background Guide to the Guidance
Webinar Schedule I. A Guide to the 340B Omnibus Guidance 340B Background Guide to the Guidance II. Stakeholder Response to the 340B Ceiling Price and Manufacturer CMP Proposed Rule Thursday, Oct. 8, 2005
More information1/16/2014. David Pointer President, SolutionsRx
David Pointer President, SolutionsRx 417.679.2203 david@pointerlaw.com 1 340B Program Overview Physician-Administered Drugs Contract Pharmacies 340B Compliance Expanding 340B Utilization 2 Federally mandated
More informationBKD NATIONAL HEALTH CARE GROUP
BKD NATIONAL HEALTH CARE GROUP PRESCRIPTION FOR 340B SUCCESS IN 2018 February 14, 2018 BRIAN BELL DIRECTOR BBELL@BKD.COM TO RECEIVE CPE CREDIT Participate in entire webinar Answer polls when they are provided
More information340B Program Update & Recommendations for Monitoring Program Compliance October
340B Program Update & Recommendations for Monitoring Program Compliance October 2 2014 Speaker Biography Ray Albertina Director Deloitte & Touche LLP +1 (314) 342 4984 ralbertina@deloitte.com Ray is a
More informationIntroduction. The Basics of the 340B Program. 340B Drug Discount Program Compliance, Audit & Enforcement Activity. Wesley R.
340B Drug Discount Program Compliance, Audit & Enforcement Activity Wesley R. Butler Wes.Butler@BBB-Law.com Introduction Caveat This presentation is intended as an overview of a complex area of law and
More informationERISA Retirement Plan Investment Management Agreements: Guidance for Plan Sponsors to Minimize Risks
Presenting a live 90-minute webinar with interactive Q&A ERISA Retirement Plan Investment Management Agreements: Guidance for Plan Sponsors to Minimize Risks Selecting 3(38) Investment Managers, Negotiating
More informationCommercial Lease Negotiations: Property and Liability Insurance, Proof of Coverage, AI and Loss Payee Issues
Presenting a live 90-minute webinar with interactive Q&A Commercial Lease Negotiations: Property and Liability Insurance, Proof of Coverage, AI and Loss Payee Issues Structuring Lease Provisions to Require
More informationAn Introduction to and Updated Regarding the 340B Federal Drug Discount Program
An Introduction to and Updated Regarding the 340B Federal Drug Discount Program Chris Roberson, JD, MPH 317.871.0000 or 877.256.8837 Raphael Health Center Picture of CHC Describe how many centers and how
More informationQDRO Drafting Boot Camp: Preparing QDROs for 401(k)s and Similar Defined Contribution Plans
Presenting a live 90-minute webinar with interactive Q&A QDRO Drafting Boot Camp: Preparing QDROs for 401(k)s and Similar Defined Contribution Plans Strategies for Family Law Practitioners to Help Ensure
More informationRenee Gravalin, Partner
Experience the Eide Bailly Difference 340B Drug Program Renee Gravalin, Partner rgravalin@eidebailly.com 701.799.5449 Agenda Proposed Changes 1 Experience the Eide Bailly Difference Created in 1992 to
More informationResolving Medicare and Medicaid Liens in Personal Injury Cases Negotiating Healthcare Liens or Claims for Reimbursement, Maximizing Settlement Awards
Presenting a live 90-minute webinar with interactive Q&A Resolving Medicare and Medicaid Liens in Personal Injury Cases Negotiating Healthcare Liens or Claims for Reimbursement, Maximizing Settlement Awards
More information340B Drug Program Compliance: Focus on Disproportionate Hospitals
340B Drug Program Compliance: Focus on Disproportionate Hospitals Part II: 340B Drug Program Compliance: Pharmacy Operations and the DSH January 29, 2014 1 Faculty Stephen J. Weiser, JD, LLM Director 312-403-4284
More informationTelemedicine Agreements: FMV, Commercial Reasonableness Compliance in Compensation Arrangements
Presenting a live 90-minute webinar with interactive Q&A Telemedicine Agreements: FMV, Commercial Reasonableness Compliance in Compensation Arrangements WEDNESDAY, AUGUST 8, 2018 1pm Eastern 12pm Central
More informationPresenting a live 90-minute webinar with interactive Q&A. Today s faculty features: Brian E. Hammell, Esq., Sullivan & Worcester, Boston
Presenting a live 90-minute webinar with interactive Q&A Buy-Sell Agreements for Corporations and LLCs: Drafting Stock Redemption, Cross-Purchase and Mixed Agreements Navigating Complex Corporate, Tax,
More informationNew Section 199A: Structuring Real Estate Transactions to Take Advantage of the Qualified Business Income Deduction
Presenting a 90-minute encore presentation featuring live Q&A New Section 199A: Structuring Real Estate Transactions to Take Advantage of the Qualified Business Income Deduction THURSDAY, JANUARY 17, 2019
More informationA Pharmacy s Guide to 340B Contract Pharmacy Services Best Practices
A Pharmacy s Guide to 340B Contract Pharmacy Services Best Prepared by: Date: September 1, 2014 Table of Contents Overview... 1 Introduction to the 340B program... 3 340B Covered Entity Eligibility...
More informationAllocating Risk in Real Estate Leases: Contractual Indemnities, Additional Insured Endorsements and Waivers of Subrogation
Presenting a live 90-minute webinar with interactive Q&A Allocating Risk in Real Estate Leases: Contractual Indemnities, Additional Insured Endorsements and Waivers of Subrogation Structuring Lease Provisions
More informationExercising Setoff and Recoupment Rights in Bankruptcy
Presenting a live 90-minute webinar with interactive Q&A Exercising Setoff and Recoupment Rights in Bankruptcy Mutuality of Obligation; Disputed Transactions; Relief From Automatic Stay TUESDAY, NOVEMBER
More information340B Compliance: Overcoming Challenges with Diversion, Duplicate Discounts, and Orphan Drug Restrictions
Presenting a live 90-minute webinar with interactive Q&A 340B Compliance: Overcoming Challenges with Diversion, Duplicate Discounts, and Orphan Drug Restrictions WEDNESDAY, JANUARY 15, 2014 1pm Eastern
More informationProperty Management and Leasing Agreements: Key Provisions for Multi-Family, Office, Retail and Industrial Properties
Presenting a live 90-minute webinar with interactive Q&A Property Management and Leasing Agreements: Key Provisions for Multi-Family, Office, Retail and Industrial Properties Navigating Fees and Expenses,
More informationPresenting a live 90-minute webinar with interactive Q&A. Today s faculty features:
Presenting a live 90-minute webinar with interactive Q&A Transactional Risk Insurance in M&A: Reps and Warranties, Contingent Liability and More Leveraging Insurance to Allocate Risk and Protect Deal Value;
More information340B Drug Pricing: Don t Become an HRSA Statistic. Wipfli LLP 1
340B Drug Pricing: Don t Become an HRSA Statistic October 13, 2017 Wipfli LLP 1 Today s Agenda 340B Drug Pricing Program Overview Program Benefit Eligibility Program in Operation Contract Pharmacy Regulatory
More informationCompletion Guaranties in Construction Lending: Key Provisions for Lenders and Guarantors
Presenting a live 90-minute webinar with interactive Q&A Completion Guaranties in Construction Lending: Key Provisions for Lenders and Guarantors TUESDAY, MARCH 6, 2018 1pm Eastern 12pm Central 11am Mountain
More informationFCPA Due Diligence in M&A Amid Increased Enforcement
Presenting a live 90-minute webinar with interactive Q&A FCPA Due Diligence in M&A Amid Increased Enforcement Developing and Risks and Implementing Post-Closing Protections WEDNESDAY, AUGUST 24, 2016 1pm
More informationCorporate Governance of Subsidiaries: Board Roles and Responsibilities, Interplay With Parent Board, Liability Risks
Presenting a live 90-minute webinar with interactive Q&A Corporate Governance of Subsidiaries: Board Roles and Responsibilities, Interplay With Parent Board, Liability Risks THURSDAY, AUGUST 16, 2018 1pm
More information340B Program: Mega Guidance, Mega Change Pershing Yoakley & Associates, PC (PYA).
340B Program: Mega Guidance, Mega Change No portion of this white paper may be used or duplicated by any person or entity for any purpose without the express written permission of PYA. For many years,
More informationClearing Title for Defects Due to Mortgage-Related Issues, Legal Description Errors, and Foreclosure
Presenting a live 90-minute webinar with interactive Q&A Clearing Title for Defects Due to Mortgage-Related Issues, Legal Description Errors, and Foreclosure Identifying and Resolving Common Title Defects
More informationWhat is the 340B Program?
Emily Cook, Partner, McDermott Will & Emery Anne S. Daly, Senior Director of Compliance, Banner Health Karolyn Woo Miles, Principal, Deloitte & Touche LLP 1 What is the 340B Program? Federal drug discount
More information6/11/2013. South Carolina Primary Health Care Association. Overview. 340B Essentials. Disclaimer. 340B Essentials. 340B Essentials
South Carolina Primary Health Care Association 2013 Clinical Network Retreat June 9, 2013 Preparing for and Surviving a 340B Audit presented by: Michael B. Glomb, Partner of Overview Key features of the
More information2/25/2016. Today s Objectives. Disclaimer WHAT S NEW IN THE WORLD OF 340B?
WHAT S NEW IN THE WORLD OF 340B? Jim Donnelly Vice President of Pharmacy Services Hudson Headwaters Health Network Jennifer Bolster Partner Hancock Estabrook, LLP. Friday, February 26 th Today s Objectives
More informationThe 340B Drug Pricing Program
The 340B Drug Pricing Program Presentation at Alliance of Community Health Plans Medical Directors and Pharmacy Directors Meeting October 2012 Avalere Health LLC Avalere Health LLC The intersection of
More informationInsurance Coverage for Statutory and Liquidated Damages and Attorney Fees: Policyholder and Insurer Perspectives
Presenting a live 90-minute webinar with interactive Q&A Insurance Coverage for Statutory and Liquidated Damages and Attorney Fees: Policyholder and Insurer Perspectives Advocating Coverage for Statutory
More informationERISA Compliance and Monitoring 401(k) Investments: Safe Harbor Rules and Appointing Advisers
Presenting a live 90-minute webinar with interactive Q&A ERISA Compliance and Monitoring 401(k) Investments: Safe Harbor Rules and Appointing Advisers TUESDAY, APRIL 3, 2018 1pm Eastern 12pm Central 11am
More informationUCC Article 9 Blanket Asset Lien Exclusions and Purchase Money Security Interests
Presenting a live 90-minute webinar with interactive Q&A UCC Article 9 Blanket Asset Lien Exclusions and Purchase Money Security Interests Navigating Statutory, Contractual and Other Exclusions to All
More information4) We will not release any information identifying hospitals or individual respondents without obtaining prior consent.
Welcome! On July 13, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule that would substantially reduce how much Medicare Part B pays 340B hospitals for non-retail drugs under
More informationTable of Contents. Executive Resources, LLC 2015, v. 2
2 Table of Contents I. Introduction II. Overview III. Contract Pharmacy and Arrangements IV. HRSA and 340B Data Base V. Software, Internal Control Systems and Management of Inventory VI. External Relationships
More information340B MEGA GUIDANCE WHAT NOW? KENTUCKY HFMA WINTER INSTITUTE JANUARY 21, 2016
340B MEGA GUIDANCE WHAT NOW? KENTUCKY HFMA WINTER INSTITUTE JANUARY 21, 2016 Brian Bell Director bbell@bkd.com Brenda Christman Managing Director bchristman@bkd.com MATERIAL COVERED TODAY The Health Resources
More informationPresenting a live 90-minute webinar with interactive Q&A. Today s faculty features:
Presenting a live 90-minute webinar with interactive Q&A Equity Joint Ventures: Structuring Capital Contribution, Waterfall and Other Payment Provisions Promoted Interest, Carried Interest, Cash Flow Splits
More informationSurvivor Benefit Plans and Military Divorce: Defending Against or Claiming Former-Spouse SBP Coverage
Presenting a live 90-minute webinar with interactive Q&A Survivor Benefit Plans and Military Divorce: Defending Against or Claiming Former-Spouse SBP Coverage WEDNESDAY, JUNE 28, 2017 1pm Eastern 12pm
More informationProtecting Business Assets From Creditors in Litigation: Strategic Choice of Entities, Avoiding Fraudulent Transfers
Presenting a live 90-minute webinar with interactive Q&A Protecting Business Assets From Creditors in Litigation: Strategic Choice of Entities, Avoiding Fraudulent Transfers TUESDAY, JULY 21, 2015 1pm
More informationPresenting a live 90-minute webinar with interactive Q&A. Today s faculty features: Scott D. Brooks, Partner, Cox Castle & Nicholson, San Francisco
Presenting a live 90-minute webinar with interactive Q&A Allocating Risk in Real Estate Leases: Contractual Indemnities, Additional Insured Endorsements, Subrogation Waivers Coordinating Lease Provisions
More informationAllocating Operating Expenses in Commercial Real Estate Leases: Negotiating Strategies for Landlords and Tenants
Presenting a live 90-minute webinar with interactive Q&A Allocating Operating Expenses in Commercial Real Estate Leases: Negotiating Strategies for Landlords and Tenants Structuring Pass-Throughs, Exclusions,
More informationPresenting a live 90-minute webinar with interactive Q&A. Today s faculty features:
Presenting a live 90-minute webinar with interactive Q&A D&O Indemnification Provisions in Governance Documents and Agreements Drafting Effective Indemnity and Advancement Agreements to Protect Directors
More information340B Drug Pricing Program
340B Drug Pricing Program Mary Stepanyan, PharmD Candidate 2018 University of Southern California, School of Pharmacy Pro Pharma Pharmaceutical Consultants Under the preceptorship of Dr. Craig Stern WHY
More informationPresenting a live 90-minute webinar with interactive Q&A. Today s faculty features:
Presenting a live 90-minute webinar with interactive Q&A M&A Escrow Agreements: Negotiation & Drafting Strategies Structuring Contract Terms, Dealing With Escrow Agents, Avoiding Conflicts With Acquisition
More informationCreatively Completing The Capital Stack: Real Estate GP Private Equity Funds
Presenting a live 90-minute webinar with interactive Q&A Creatively Completing The Capital Stack: Real Estate GP Private Equity Funds Structuring Key Deal Terms Regarding Distribution, Sharing of Promote
More informationAsset Sale vs. Stock Sale: Tax Considerations, Advanced Drafting and Structuring Techniques for Tax Counsel
Presenting a live 90-minute webinar with interactive Q&A Asset Sale vs. Stock Sale: Tax Considerations, Advanced Drafting and Structuring Techniques for Tax Counsel TUESDAY, AUGUST 2, 2016 1pm Eastern
More information340B Program Contract Pharmacy Self-Audit Tool: Diversion
Page 1 Purpose: The purpose of the Contract Pharmacy Self-Audit Tools is to improve contract pharmacies compliance with the 340B Program requirements. Covered entities remain responsible for the 340B drugs
More informationUsing Partnership Flips to Finance Renewable Energy Projects: Evaluating Tax Risks, Navigating IRS Safe Harbors
Presenting a live 90-minute webinar with interactive Q&A Using Partnership Flips to Finance Renewable Energy Projects: Evaluating Tax Risks, Navigating IRS Safe Harbors THURSDAY, JULY 26, 2018 1pm Eastern
More informationUCC Article 9 Blanket Asset Lien Exclusions and Purchase Money Security Interests
Presenting a live 90-minute webinar with interactive Q&A UCC Article 9 Blanket Asset Lien Exclusions and Purchase Money Security Interests Navigating Statutory, Contractual and Other Exclusions to All
More informationFCPA Due Diligence in M&A: Leveraging the New DOJ Opinion Procedure Release
Presenting a live 90-minute webinar with interactive Q&A FCPA Due Diligence in M&A: Leveraging the New DOJ Opinion Procedure Release Mitigating Pre-Closing Risks and Implementing Post-Closing Protections
More informationThe 340B Program: Challenges and Opportunities
The 340B Program: Challenges and Opportunities March 2015 Thomas Barker Igor Gorlach Foley Hoag LLP Overview Overview and History of the 340B Program ACA s Changes to the 340B Program Recent Developments
More informationfor Landlords and Tenants Negotiating Insurance, Indemnity and Mutual Waiver of Subrogation Provisions
Presenting a live 90 minute webinar with interactive Q&A Commercial Leases: Risk Mitigation Strategies for Landlords and Tenants Negotiating Insurance, Indemnity and Mutual Waiver of Subrogation Provisions
More informationThe Federal 340B Drug Discount Program. Compliance and Lessons Learned. Jason Reddish September 24, 2014
The Federal 340B Drug Discount Program Compliance and Lessons Learned Jason Reddish September 24, 2014 About Me Jason Reddish Attorney Powers Pyles Sutter & Verville PC 1501 M Street NW, 7 th Floor Washington,
More informationKey Commercial Lease Provisions and SNDAs That Concern Lenders in Mortgage and Leasehold Financing
Presenting a live 90-minute webinar with interactive Q&A Key Commercial Lease Provisions and SNDAs That Concern Lenders in Mortgage and Leasehold Financing Identifying and Correcting Red Flags That Negatively
More informationUsing Partnership Flips to Finance Renewable Energy Projects: Evaluating Tax Risks, Navigating IRS Safe Harbors
Presenting a live 90-minute webinar with interactive Q&A Using Partnership Flips to Finance Renewable Energy Projects: Evaluating Tax Risks, Navigating IRS Safe Harbors THURSDAY, JANUARY 26, 2017 1pm Eastern
More informationTax Challenges for NPO Counsel: Excess Benefit Transactions for Executive Comp and Other Financial Dealings
Presenting a live 110-minute teleconference with interactive Q&A Tax Challenges for NPO Counsel: Excess Benefit Transactions for Executive Comp and Other Financial Dealings Identifying Prohibited Transactions
More information10/2/2015. CPAs and ADVISORS 340B: COMPLIANCE MATTERS AND HERE S WHY MICHAEL R. EARLS, CPA DIRECTOR. experience access // 2 // experience access
CPAs and ADVISORS experience access // 340B: COMPLIANCE MATTERS AND HERE S WHY MICHAEL R. EARLS, CPA DIRECTOR MATERIALS COVERED TODAY 340B Program Evolution, Purpose & Benefits HRSA & Manufacturer Audits
More informationDrafting Asset Purchase Agreements: Reps, Warranties, Covenants, Conditions, Indemnity and Other Key Provisions
Presenting a live 90-minute webinar with interactive Q&A Drafting Asset Purchase Agreements: Reps, Warranties, Covenants, Conditions, Indemnity and Other Key Provisions TUESDAY, DECEMBER 15, 2015 1pm Eastern
More information340B Program New Developments and Increasing Scrutiny
340B Program New Developments and Increasing Scrutiny Todd Nova Hall Render tnova@hallrender.com Wisconsin Office of Rural Health Hospital Finance Workshop August 24, 2012 What We Will Cover 2 1 340B Program
More informationBest Efforts and Commercially Reasonable Efforts in M&A Agreements: Drafting and Interpretation Challenges
Presenting a live 90-minute webinar with interactive Q&A Best Efforts and Commercially Reasonable Efforts in M&A Agreements: Drafting and Interpretation Challenges Lessons From Case Law for Interpreting
More informationPrivate Investment Funds and Tax Reform
Presenting a live 90-minute webinar with interactive Q&A Private Investment Funds and Tax Reform Carried Interest, QBI and Interest Deductions, Sale of Partnership Interests, Computation of UBTI, and More
More informationPresenting a live 90-minute webinar with interactive Q&A. Today s faculty features:
Presenting a live 90-minute webinar with interactive Q&A Keys To Equity Financing: The Compliance Requirements for Lenders and Borrowers Structuring Loans Secured by Stock, Hedge Fund Shares, 40 Act Companies
More informationData Breaches in ERISA Benefit Plans: Prevention and Response
Presenting a live 90-minute webinar with interactive Q&A Data Breaches in ERISA Benefit Plans: Prevention and Response Navigating Regulations Governing Self and Fully Insured Plans; Complying with Notice
More informationMinority Investors in LLCs: Contractual Limitations, Waivers of Fiduciary Duties, Other Key Provisions
Presenting a live 90-minute webinar with interactive Q&A Minority Investors in LLCs: Contractual Limitations, Waivers of Fiduciary Duties, Other Key Provisions Protecting Minority Interests, Choice of
More informationPersonal Injury Claims for Uber and Lyft Accidents: Navigating Complex Liability and Insurance Coverage Issues
Presenting a live 90-minute webinar with interactive Q&A Personal Injury Claims for Uber and Lyft Accidents: Navigating Complex Liability and Insurance Coverage Issues WEDNESDAY, JUNE 20, 2018 1pm Eastern
More informationUsing Inverted Leases to Finance Renewable Energy Projects
Presenting a live 90-minute webinar with interactive Q&A Using Inverted Leases to Finance Renewable Energy Projects Evaluating Tax Risks, Navigating Structural Variations, Leveraging Pass-Through Election
More informationPresenting a live 90-minute webinar with interactive Q&A. Today s faculty features: Matthew B. Grunert, Partner, Andrews Kurth Kenyon, Houston
Presenting a live 90-minute webinar with interactive Q&A SEC s Pay Ratio Disclosure Rule for CEO and Median Employee Compensation Data Gathering, Calculation Methodologies, Preparing for Heightened Stakeholder
More informationAmerica s Voice for Community Health Care
America s Voice for Community Health Care The National Association of Community Health Centers (NACHC) represents Community and Migrant Health Centers, as well as Health Care for the Homeless and Public
More informationPresenting a live 90-minute webinar with interactive Q&A. Today s faculty features:
Presenting a live 90-minute webinar with interactive Q&A Qualified Opportunity Zones: New Tax Incentives for Commercial Real Estate and Other Investments Deferred Capital Gains and Tax Abatement Under
More informationPrivate Equity Waterfall and Carried Interest Provisions: Economic and Tax Implications for Investors and Sponsors
Presenting a live 90-minute Encore Presentation of the Webinar with Live, Interactive Q&A Private Equity Waterfall and Carried Interest Provisions: Economic and Tax Implications for Investors and Sponsors
More informationPresenting a live 90-minute webinar with interactive Q&A. Today s faculty features:
Presenting a live 90-minute webinar with interactive Q&A Drafting Standstills in Intercreditor Agreements: Balancing Rights and Remedies of Junior and Senior Lienholders Structuring Duration, Commencement,
More informationHigh Volatility Commercial Real Estate Loans: Guidance for Developers and Lenders on HVCRE Rules and Loan Covenants
Presenting a 90 minute encore presentation High Volatility Commercial Real Estate Loans: Guidance for Developers and Lenders on HVCRE Rules and Loan Covenants Navigating Borrower Contributed Capital Rules,
More informationVA Benefits and Medicaid Eligibility
Presenting a live 90-minute webinar with interactive Q&A VA Benefits and Medicaid Eligibility Meeting Complex Requirements for Benefits Qualification and Application THURSDAY, FEBRUARY 16, 2012 1pm Eastern
More informationPresenting a live 110-minute teleconference with interactive Q&A
Presenting a live 110-minute teleconference with interactive Q&A Valuation Challenges With $10 Million-and-Under Businesses Avoiding Mistakes With Built-In Gains and Taxes, Misuse of Market Data and Other
More informationM&A Indemnification Deal Terms: 2017 Survey Results
Presenting a 60-minute encore presentation featuring live Q&A M&A Indemnification Deal Terms: 2017 Survey Results What's Market for Negotiating and Drafting Private Target Company Indemnification Terms
More information340B MEGA GUIDANCE WHAT NOW? HFMA REGION 6 DECEMBER 16, 2015
340B MEGA GUIDANCE WHAT NOW? HFMA REGION 6 DECEMBER 16, 2015 Brian Bell Director bbell@bkd.com Claire Torrella Manager ctorrella@bkd.com MATERIAL COVERED TODAY The Health Resources and Services Administration
More informationPresenting a live 90-minute webinar with interactive Q&A. Today s faculty features: Elizabeth A. Gartland, Esq., Fenwick & West, San Francisco
Presenting a live 90-minute webinar with interactive Q&A Structuring Management Carve-Out Plans for Privately Held Corporations: Mechanics, Tax Obstacles and Optimization Guidance for Employee Benefits
More informationDrafting Shareholder Agreements for Private Equity M&A Deals
Presenting a live 90-minute webinar with interactive Q&A Drafting Shareholder Agreements for Private Equity M&A Deals Structuring Provisions on Board Composition and Duties, Drag-Along, Tag-Along, Information
More informationThe 340B drug discount program was created in 1992
Proposed Rule Changes for 340B Programs: Overview and Impact Anthony Zappa, PharmD, MBA Specialty Healthcare Benefits Council The 340B drug discount program was created in 1992 as a means for certain nonprofit
More informationScott J. Bakal, Partner, Neal Gerber & Eisenberg, Chicago Robert C. Stevenson, Attorney, Skadden Arps Slate Meagher & Flom, Washington, D.C.
Presenting a live 90-minute webinar with interactive Q&A : Tax Basis Step-Up Through Deemed Asset Sale Treatment Structuring Qualifying Stock Dispositions for Partnership and Private Equity Acquirers WEDNESDAY,
More informationMedicaid Overpayments: Challenging State Audit Allegations of Overpayment and the Use of Statistical Sampling and Extrapolation
Presenting a live 90-minute webinar with interactive Q&A Medicaid Overpayments: Challenging State Audit Allegations of Overpayment and the Use of Statistical Sampling and Extrapolation TUESDAY, OCTOBER
More informationContract Pharmacy Relationships
Contract Pharmacy Relationships What is a contract pharmacy? 1 What is a contract pharmacy? Dispenses drugs to FQHC patients on behalf of FQHC Contract between FQHC and pharmacy Typically pharmacy not
More informationERISA Pre-Approved and Customized Benefit Plans: Overhauled IRS Procedures and Determination Letter Process
Presenting a live 90-minute webinar with interactive Q&A ERISA Pre-Approved and Customized Benefit Plans: Overhauled IRS Procedures and Determination Letter Process TUESDAY, NOVEMBER 14, 2017 1pm Eastern
More informationReporting Costs of Health Insurance on Employee W-2s: New Requirements
Presenting a live 110-minute teleconference with interactive Q&A Reporting Costs of Health Insurance on Employee W-2s: New Requirements Mastering the Procedures for Disclosing and Valuing Coverage Starting
More informationIP Agreements: Structuring Indemnification and Limitation of Liability Provisions to Allocate Infringement Risk
Presenting a live 90-minute webinar with interactive Q&A IP Agreements: Structuring Indemnification and Limitation of Liability Provisions to Allocate Infringement Risk TUESDAY, SEPTEMBER 1, 2015 1pm Eastern
More informationM&A Buyer Protection Beyond Indemnification and Escrows
Presenting a live 90-minute webinar with interactive Q&A M&A Buyer Protection Beyond Indemnification and Escrows Structuring Deal-Specific and Often Overlooked Acquisition Provisions to Minimize Buyer's
More informationEstate Planning and Tax Reform: Wealth Transfer Structures Under the New Tax Law
Presenting a live 90-minute webinar with interactive Q&A Estate Planning and Tax Reform: Wealth Transfer Structures Under the New Tax Law WEDNESDAY, FEBRUARY 7, 2018 1pm Eastern 12pm Central 11am Mountain
More informationConstruction OCIP/CCIP Insurance Programs: Potential Coverage Gaps and Other Coverage Pitfalls
Presenting a live 90-minute webinar with interactive Q&A Construction OCIP/CCIP Insurance Programs: Potential Coverage Gaps and Other Coverage Pitfalls Coordinating With Other Policies; Navigating Issues
More informationPresenting a 90-minute encore presentation featuring live Q&A. Today s faculty features:
Presenting a 90-minute encore presentation featuring live Q&A Private Equity Waterfall and Carried Interest Provisions: Economic and Tax Implications for Investors and Sponsors Distributions, Clawbacks
More informationBuilder's Risk Insurance for Construction Projects: Legal Issues Evaluating Scope of Coverage and Resolving Coverage Disputes
Presenting a live 90 minute webinar with interactive Q&A Builder's Risk Insurance for Construction Projects: Legal Issues Evaluating Scope of Coverage and Resolving Coverage Disputes WEDNESDAY, JUNE 29,
More information340B Compliance, Audits & Opportunities
340B Compliance, Audits & Opportunities NW Ohio HFMA February 15, 2018 David Layne, CPA Manager HRSA Audits Bizzell Group-Silver Spring, Maryland Prior Hospital experience Many are pharmacists Experienced
More informationFollowing this presentation, attendees should be able to: Identify key events in 340B landscape that occurred in 2015 and 2016.
Following this presentation, attendees should be able to: Identify key events in 340B landscape that occurred in 2015 and 2016. Identify critical components of a compliance plan. List the different types
More information